EMA Authorised: Truxima (rituximab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Truxima (rituximab) by Celltrion Healthcare Hungary Kft. as a biosimilar rituximab for several indications including Non-Hodgkin lymphoma, Rheuma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis

Drugs mentioned

• TRUXIMA (rituximab-abbs)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Wegener Granulomatosis;Leukemia, Lymphocytic, Chronic, B-Cell;Microscopic Polyangiitis. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 25/09/2025